Study scale: Briefly, neural data were divided into 1s chunks and randomly shuffled n=10000 times, then rn was recalculated for each cell in each shuffle to give a distribution of values rN.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Here, we investigate VIP-IN function at the circuit and behavioral level by performing in vivo 2-photon calcium imaging in awake wild-type (WT) and Scn1a+/− mice.
Study design
We used an established 2P calcium imaging paradigm to simultaneously assess the activity of VIP-INs and pyramidal neurons during behavioral-state transition in vivo.
Participants or experimental system
To validate that our results indeed reflected the activity of excitatory pyramidal neurons, we recorded from pyramidal cell-specific Slc17a7-Cre.WT mice injected with Cre-dependent GCaMP7s under otherwise identical conditions, thereby limiting GCaMP7s expression to a genetically identified excitatory neuron population.
Study scale
Briefly, neural data were divided into 1s chunks and randomly shuffled n=10000 times, then rn was recalculated for each cell in each shuffle to give a distribution of values rN.
Intervention or exposure
For 2P imaging experiments, VIP-INs from double transgenic Scn1a.VIP-Cre and WT.VIP-Cre littermates from the cross described above were labeled via stereotaxic injection of AAV9.pCAG.Flex.tdTomato.WPRE.
Comparator
Not reported in the declared source.
Outcomes examined
We tested this by injecting a low dose of the muscarinic agonist pilocarpine (10 mg/kg; typical convulsant doses are 300–400 mg/kg) and measured activity of individual cells within the same imaging field during both resting and locomotion epochs before and after pilocarpine injection (Figure 5A).
Limitations and uncertainty
One important caveat of our experimental setup is that while tdT− non-VIP neurons predominantly represent excitatory neurons in layer 2/3, this may also include other non-VIP-IN populations including SST-INs, which may be differentially affected relative to pyramidal neurons by both loss of Scn1a and impairment of VIP-IN excitability.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Our objective was to determine whether Lu AG09222, an investigational humanized monoclonal antibody directed against PACAP ligand, would inhibit the PACAP-signaling cascade by abolishing its vasodilatory and headache-inducing abilities.
Study design
In a randomized, double-blind, parallel-group, single-dose, placebo-controlled study of Lu AG09222, healthy volunteers aged 18–45 years without history of headache disorders were randomly allocated to three treatment sequences (1:2:2) on two experimental infusion visits with 9 ± 3 days’ interval: placebo + saline + saline (n = 5), placebo + PACAP38 + VIP (n = 10), and Lu AG09222 + PACAP38 + VIP (n = 10).
Participants or experimental system
All randomized participants who received either placebo or Lu AG09222 were included in the safety analysis; all participants who received an infusion of PACAP38 or saline and had a valid pre-infusion STA diameter measurement and a valid AUCSTA-PACAP38 measurement on visit 1 were included in analyses related to the PACAP38 infusion; and all participants who received a VIP or saline infusion and had a valid pre-infusion STA diameter measurement and a valid AUCSTA-VIP measurement on visit 2 were included in analyses related to the VIP infusion.
Study scale
Not reported in the declared source.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
This was a phase 1, interventional, randomized, double-blind, parallel-group, placebo-controlled, single-dose study investigating the effect of Lu AG09222 in a headache model with healthy volunteers.
Outcomes examined
Vascular parameters (superficial temporal artery [STA] diameter and radial artery [RA] diameter measured by high-resolution ultrasonography; facial flushing measured by speckle contrast imager), heart rate and headache were documented before Lu AG09222 or placebo infusion and PACAP38 or saline infusion at visit 1 and before VIP or saline infusion at visit 2.
Limitations and uncertainty
This study has a relatively small sample size.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
To identify putative DA neurons, DAT-Cre::Ai14 mice were used.
Study scale
C57BL/6 (n = 10), DAT-ires-cre (n = 4), DAT-ires-Cre::Ai14 (n = 17), and VGlut2-ires-Cre::Ai14 (n = 9) were used in this study.
Intervention or exposure
AAV5-EF1α-DIO-hChR2-EYFP (200 nl; catalog #20298-AAV5, Addgene, MA, USA) was injected into the DR-PAG region (in mm; AP: −4.3, ML: +1.0, from bregma; DV: −2.7 angled at 22°, from the brain surface) using a microinjector (Nanoject II, Drummond Scientific Company, PA, USA).
Comparator
Not reported in the declared source.
Outcomes examined
First, we examined the expression of DAT in the DR-PAG region (DATDR-PAG), depending on the expression of tdTomato of DAT-cre::Ai14 mice.
Limitations and uncertainty
Therefore, in the present study, we aimed to clarify the potential heterogeneity of DADR-PAG neurons projecting to the CeA and BNST.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Study scale: In December 2020, the sponsor submitted a modified protocol and statistical analysis plan to FDA in consultation with the IRB and DMC extending the trial to 60 days of observation and a sample size of 198 subjects.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.
Study design
A multicenter, placebo-controlled trial.
Participants or experimental system
A total of 196 patients with COVID-19 respiratory failure.
Study scale
In December 2020, the sponsor submitted a modified protocol and statistical analysis plan to FDA in consultation with the IRB and DMC extending the trial to 60 days of observation and a sample size of 198 subjects.
Intervention or exposure
Not reported in the declared source.
Comparator
Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.
Outcomes examined
The key secondary end point was survival at 60-day posttreatment, as ascertained by study-site personnel.
Limitations and uncertainty
Another limitation was the randomization imbalance in baseline ventilation status as determined by the NIAID score.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Narrative review · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not reported in the declared source.
Participants or experimental system
Not reported in the declared source.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Not reported in the declared source.
Outcomes examined
The functional roles of the circadian clock of AVP neurons in the SCN were evaluated by genetically manipulating AVP neurons using the Cre-loxP system.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The present study examines the response of neurons of PCG innervating uterine horn to axotomy caused by partial hysterectomy in the domestic pig animal model.
Study design
Not reported in the declared source.
Participants or experimental system
In remaining 5 animals only sham operation was performed.
Study scale
Not reported in the declared source.
Intervention or exposure
Not reported in the declared source.
Comparator
Preabsorption controls of antisera were done by preincubating the antibody with the specific immunogen (10 μg/ml) for 24 h under slow stirring at 4°C. Negative controls were performed by omitting all primary or secondary antibodies in the staining protocol.
Outcomes examined
Results were analyzed by Wilcoxon signed-rank test (Statistica 13.3, TIBCO Software Inc.).
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Using in vivo two-photon imaging and genetically encoded fluorescent indicators, we systematically investigate the GABA/glutamate/calcium dynamics of the primary visual cortex with cell-type specificity during isoflurane anaesthesia.
Study design
Here, we measured the dynamics of two major cortical neurotransmitters, gamma-aminobutyric acid (GABA) and glutamate, through in vivo two-photon imaging and genetically encoded neurotransmitter sensors in a cell type-specific manner in the primary visual (V1) cortex.
Participants or experimental system
The following mice (2-4 months old) were used in the experiments: VIP-ires-Cre, JAX Stock No. 010908; PV-ires-Cre, JAX Stock No. 008069; SOM-ires-Cre, JAX Stock No. 013044; and C57BL/6J, JAX Stock No. 000664.
Study scale
Not reported in the declared source.
Intervention or exposure
C57BL/6J mice were injected with the 1:1 virus mixture of AAV-CAMKII-cre with AAV-DIO-GCaMP6m, AAV-DIO-iGABASnFR, or AAV-DIO-iGluSnFR prepared on the day of injection.
Comparator
Not reported in the declared source.
Outcomes examined
To confirm the specific expression of the genetically encoded indicators GCaMP6m, iGABASnFR, and iGluSnFR in pyramidal, PV, SOM, and VIP neurons, we performed glutamate/PV/SOM/VIP immunohistochemistry.
Limitations and uncertainty
Due to the limitation of spatiotemporal resolution, these results can reflect only the averaged glutamate level of the local neuronal population under stable anaesthesia and are far from sufficient to reveal the glutamate transients during the induction of unconsciousness.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To test how abundant ChAT-VIP input to L1 interneurons is in mouse prefrontal cortical slices, we recorded from an additional set of 118 L1 interneurons and activated ChAT-VIP neurons with blue-light pulses.
Study design
Following acquisition of baseline performance, rats were assigned to the testing phase where the task comprised 100 consecutive trials with a random assignment of laser-ON or laser-OFF trials.
Participants or experimental system
Since ChAT-VIP cells release ACh in the mPFC, similar to basal forebrain (BF) cholinergic inputs, we also tested whether inhibiting ChAT-VIP interneurons affected attention behaviour distinct from inhibiting BF cholinergic inputs to mPFC.
Study scale
No GABAergic IPSCs at 0 mV were observed following light-evoked activation of ChAT-VIP interneurons (n = 0/8).
Intervention or exposure
To optimize rat BF injection location, as we previously did for mouse BF6, four BF coordinates were used: (a) AP −1.20 mm; ML 2.0 mm; DV −6.8 and 8.9 (1 μl in total) or −7.8 mm (0.5 μl) from skull; (b) AP −0.60 mm; ML 2.0 mm; DV −8.4 mm from skull; (c) AP 0.00 mm; ML 1.6 mm; −8.7 and −8.4 (1 μl in total) or −8.6 mm (0.5 μl) from skull; (d) AP + 0.84 mm; 0.9 mm; DV −7.9 and −8.3 (1 μl in total) or −8.1 mm (0.5 μl) from skull.
Comparator
For each animal, behavioural performance during laser-ON trials was compared with its own behavioural performance during laser-OFF trials.
Outcomes examined
GAD67 staining was performed with primary antibody anti-GAD67 raised in mouse (1:1200, MAB5406 clone 1G10.2, Chemicon Millipore) and visualized using donkey anti-mouse Alexa 546 (1:400, A10036, Molecular probe).
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: Fourteen days after the operation, rats (n = 10 SHAM and n = 24 BCCAO) were killed with anesthetic and the eyes were processed for histology.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Fourteen days after the operation, rats (n = 10 SHAM and n = 24 BCCAO) were killed with anesthetic and the eyes were processed for histology.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To examine ASMase distribution on the apical surface of differentiated non-CF pHBEs, the above procedure was followed but without the membrane permeabilization step.
Study design
Not reported in the declared source.
Participants or experimental system
CF lung tissue was obtained from F508del/F508del patients after lung transplantation with informed written consent and following protocols approved by the Institutional Review Boards of the Institut de recherches cliniques de Montréal and McGill University.
Study scale
Not reported in the declared source.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
To visualize endogenous CFTR and the effects of VIP, cells were exposed bilaterally to control medium or medium containing 200 nM VIP (Sigma-Aldrich) for 1 h, then gently washed and scraped from the insert into PBS and centrifuged onto glass coverslips (500 rpm, 5 min; Cytospin 4; Thermo Fisher Scientific).
Outcomes examined
To measure short-circuit current (Isc), cells were seeded on fibronectin-coated polyester membrane inserts (0.4 µM pore diameter, 6.5 mm diameter; Corning Costar) and kept submerged until the transepithelial electrical resistance reached >400 Ω⋅cm2 as measured using an epithelial volt-ohmmeter (World Precision Instruments).
Limitations and uncertainty
Although the clusters (in contrast to the platforms) were optical resolution–limited size in the images and this approach provides only an upper estimate of microdomain area, measuring the subdiffraction-sized aggregates more accurately would only strengthen our conclusion regarding the different dimensions of rafts versus platforms.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
To evaluate the efficacy and safety of Tongfu powder for external application on Shénquè (the umbilicus, hereafter, Tongfu powder) versus mosapride in acute pancreatitis (AP) patients with gastrointestinal dysfunction.
Outcomes examined
The endpoint of the study was death at 3 months.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked